Entinostat
- Generic Name
- Entinostat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H20N4O3
- CAS Number
- 209783-80-2
- Unique Ingredient Identifier
- 1ZNY4FKK9H
- Background
Entinostat is under investigation for the treatment and other of Volunteers, Breast Cancer, Human Volunteers, and Normal Volunteers. Entinostat has been investigated for the treatment of Non-Small Lung Cancer, Epigenetic Therapy.
- Indication
联合芳香化酶抑制剂用于治疗激素受体（HR）阳性、人类表皮生长因子受体-2（HER-2）阴性，经内分泌治疗复发或进展的局部晚期或转移性乳腺癌患者。
- Associated Conditions
- -
- Associated Therapies
- -
Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2019-05-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 94
- Registration Number
- NCT00387465
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Sidney Kimmel Cancer Center, San Diego, California, United States
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAdult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLLAdult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARAAlkylating Agent-Related Acute Myeloid LeukemiaRecurrent Adult Acute Myeloid LeukemiaChronic Myelomonocytic Leukemia
- Interventions
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2017-02-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 197
- Registration Number
- NCT00313586
- Locations
- 🇺🇸
Clements University Hospital, Dallas, Texas, United States
🇺🇸Union Hospital of Cecil County, Elkton, Maryland, United States
🇺🇸Hematology and Oncology Associates, Chicago, Illinois, United States
MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
- First Posted Date
- 2005-01-10
- Last Posted Date
- 2019-10-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 63
- Registration Number
- NCT00101179
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸Mount Sinai Hospital, New York, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas
- Conditions
- Adult Grade III Lymphomatoid GranulomatosisAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueIntraocular LymphomaNodal Marginal Zone B-cell LymphomaRecurrent Adult Burkitt LymphomaRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Adult T-cell Leukemia/Lymphoma
- Interventions
- First Posted Date
- 2004-12-09
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00098891
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-03-15
- Target Recruit Count
- 75
- Registration Number
- NCT00020579
- Locations
- 🇺🇸
National Naval Medical Center, Bethesda, Maryland, United States
🇺🇸Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸NCI - Center for Cancer Research, Bethesda, Maryland, United States
MS-275 in Treating Patients With Hematologic Cancer
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.